NaTHNaC Telephone Advice Line for health professionals
Due to staff shortages, opening hours for the advice line service have been revised
Mefloquine shortage
Shortage of 250mg mefloquine (Lariam) antimalarial tablets in the United Kingdom (UK) until January 2026
Mpox outbreak in Africa: clade I mpox virus infection
As of 4 September 2025, the mpox outbreak no longer continues to meet the World Health Organization (WHO) criteria of a public health emergency of international concern (PHEIC)
Changes to country yellow fever certificate requirements
Important reminder to look out for updates to country yellow fever certificate requirements
Ebola virus disease in DRC
Health authorities in the Democratic Republic of the Congo have confirmed an outbreak of Ebola virus disease
Chikungunya vaccination information
Chikungunya vaccinations authorised in the UK including updates on recent possible serious adverse events in older people and JCVI advice
Professional Diploma in Travel Health (online), LSTM
The next Professional Diploma in Travel Health run by the Liverpool School of Tropical Medicine, begins on 22 September 2025
Cyclospora travel reminder
Remember – follow good food and water hygiene advice abroad to protect yourself from a parasite called Cyclospora
Invasive meningococcal disease reported in Umrah pilgrims in 2025
If you are planning to visit Saudi Arabia for Umrah in 2025, make sure you are vaccinated
UKHSA publishes travel-associated infections report
Case numbers of selected travel-associated infections reported in England, Wales and Northern Ireland: January to June 2025
Contaminated medicine
On 13 October 2025, the World Health Organization (WHO) published a Medical Product Alert about oral cold medicine in India contaminated with diethylene glycol (toxic to humans) linked to clusters of acute illness and deaths of children in India. These medicines are COLDRIF, Respifresh TR and ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals and Shape Pharma. These contaminated oral liquid medicines named in this alert are unsafe, pose a significant risk and can cause severe, potentially life-threatening illness. Their use, especially in children, may result in serious injury or death. Please see WHO Medical Product Alert N°5/2025: Substandard (contaminated) oral liquid medicines for further details.
Extensively drug-resistant gonorrhoeae in Germany
As of 9 October 2025, a total of four locally acquired cases of extensively drug-resistant (XDR) Neisseria gonorrhoea were reported in 2025. A strong molecular connection was confirmed between three of these cases. All infections occurred in heterosexual adults living in the same geographical region of Germany, with no recent history of travel abroad. These are the first known locally acquired XDR/MDR Neisseria gonorrhoea cases in Germany. Please see UKHSA guidance on gonorrhoea for further details.
cVDPV1 in Laos
As of 16 October 2025, one circulating vaccine-derived poliovirus type 1 (cVDPV1) case was confirmed, with onset of paralysis on 3 September 2025, in Savannahket. This is the first case in Laos this year and is a new emergence. Please see our Topics in Brief article for further details on polio.
Rift Valley fever in Senegal
As of 16 October 2025, a total of 196 confirmed Rift Valley fever cases, including 21 deaths have now been reported in Senegal for 2025. Dakar region is newly affected and has reported one case. The majority of cases (179) have been reported from Saint-Louis region. Cases have also been reported in Fatick, Louga and Matam regions. Please see UKHSA guidance on Rift Valley fever for further details.
Chikungunya in Pakistan
As of September 2025, over 1,000 suspected cases of chikungunya have been reported in Pakistan during 2025. An increase in case numbers was noted between 4 May and 21 June 2025. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Somalia
An outbreak of chikungunya has been reported in Sool region, January – June 2025. A total of 488 suspected cases were recorded. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Indonesia
As of 31 July 2025, a total of 3,608 confirmed chikungunya cases have been reported across 19 provinces of Indonesia during 2025. This represents on increase in case numbers compared to the same period in 2024 when 1,399 cases were recorded. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Malaysia
As of 2 August 2025, a total of 40 chikungunya cases (no deaths) have been reported in Malaysia during 2025. Three separate clusters were detected and successfully contained indicating an effective public health response. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in Philippines
As of 16 August 2025, a total of 628 cases of chikungunya (including one death) have been reported in the Philippines since the start of 2025. Please see our Topics in Brief article for further details on chikungunya.
Chikungunya in USA
On 14 October 2025, the New York State Department of Health reported a locally acquired case of chikungunya in Nassau County on Long Island. This is the first locally acquired case ever reported in New York State and the first contracted in the USA since 2019. Please see our Topics in Brief article for further details on chikunungya.
The Yellow Fever Zone
Get TravelHealthPro on your site
Travellers in Scotland
|
Travellers based in Scotland should check the NHS inform website for further information on accessing travel health services. |
 |
The Yellow Fever Zone
Clinical and administrative resources for health professionals and other staff responsible for administering yellow fever vaccine and for those managing a YFVC
Get TravelHealthPro on your site
Integrate features of TravelHealthPro into your own website with our API and widget
Welcome to TravelHealthPro
A short introduction to using the TravelHealthPro website for travellers and health professionals
